Stop MTX and increase folic acid to 5 mg/day for pts who find themselves with an unintentional #pregnancy. -@CuoghiE #ACR22 @rheumnow https://t.co/uChPU6zrwv

GUS (compared to RIS) uniquely binds both CD64+ myeloid cells and IL-23. CD64+ mononuclear phagocytes are enriched in the psoriatic skin and serve as the dominant IL-23 source. Does this lead to a change in clinical response? Abs 1487 #ACR22 @RheumNow https://t.co/P512bxSxRn

• Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23 - ACR M…

Aim for drug free remission in early RA? After 1 yr remission Pts randomized to stop Rx vs 1/2 dose. More flares if no Rx. For 1/2 dose if 2 yrs remission randomize to stop or stay at 1/2 dose. 2X more flares if d/c Rx. Abst2013 Arctic rewind #ACR22 @rheumnow #ACRBest Relevant ? https://t.co/nfQPExhbYj

Once again, high BMI and smoking associated with substantial decrease in TNFi response for treatment of axSpA. Easier said than done however. How are you helping pts lose weight or stop smoking? Abs#1510 @RheumNow #ACR22 https://t.co/ircLkuXhCs

Fulvio et al. Labial gland US to identify lymphoma in Sjogrens. OMERACT score of 3 in 100% of lymphoma and 35% non-lymphoma @RheumNow #ACR22 Abstr#1254 https://t.co/aspctOfGp8 https://t.co/CLhN2PTvaS

• Ultra High‐Frequency Ultrasound of Labial Salivary Glands in Primary Sjögren’s …

‼️FAP (fibroblast activation protein) PET-CT in PsA‼️ ⚡️synovial and entheseal accum in PsA v HC ⚡️correlation of uptake with pain scores ⚡️IL-17A ⬇️ FAP, with arrest joint damage ⚡️persistent FAP - ⬆️ prog joint damage ❓new T2T in PsA❓ #ACR22 @RheumNow Abst#1602

Gut microbiota of axSpA pts who underwent bDMARD tx for one year more closely resembled controls. Unique enrichment of Collinsella in axSpA patients remained stable across time & tx, suggesting it may be a disease biomarker. Abs 1162 #ACR22 @RheumNow https://t.co/SjwORWp6IU https://t.co/rLlu4jGCfd

• Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthriti…

How many rheumatologists are managing psoriasis themselves? Or dermatologists managing arthritis themselves? Survey shows <50% rheum collaborate with derm Need updated EMRs and additional education Abs#1502 @RheumNow #ACR22 https://t.co/1okhxFAbUS

⚡️PRESTO⚡️ 📈PsA prediction tool in psoriasis Risk of PsA at 1yr ⬆️: 👉younger 👉male 👉FHx Psoriasis 👉back stiffness 👉stiffness level 👉nail pitting 👉biologic use 👉⬆️ pain and global health (AUC 72.3,95%CI 65.5,79.1) #ACR22 @RheumNow Abst#1612

Plenary: Real-world observational study >1500 pts with IA, 1 year retention infliximab biosimilar CT-P13 to GP1111 switch was high. Retention was higher in originator-experienced (92vs83%) & low disease activity Nabi H, DANBIO Abs1112 https://t.co/z84AMUS3GK #ACR22 @RheumNow https://t.co/SgGhd33Esl

• Biosimilar-to-Biosimilar Switching in Routine Care – Results on &gt;1,600 Patie…

Plenary: Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s ◦ Favourable safety profile ◦ Well-tolerated over 24 Wks ◦ Improved ESSDAI, salivary flow, Igs ◦ May be first effective oral disease-modifying therapy for SS Dorner T Abs1113 https://t.co/FkgJpwKAJL #ACR22 @RheumNow https://t.co/znxMc27EBI

• Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a…

Frailty in Vasculitis Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at #ACR22 Convergence. https://t.co/aMpcBhT5yE https://t.co/rPgA19dT0W

• https://bit.ly/3DVtSGQ

Does MTX dose matter for COVID mRNA vaccine immunogenicity in RA pts? Single-center (n=126) with one MTX dose WH post-each vaccine Similar humoral response Big error bars suggest other factors more important ABST0913 #ACR22 @RheumNow (not pretty graphs but data interesting!) https://t.co/FFfTWiNjUY

Henry @EBRheum et al. Less than 1 in 6 recommendations from ACR/EULAR informed by comparative effectiveness RCT. Many receive strong recommendation despite low/very low LOE. @RheumNow #ACR22 Abstr#1284 https://t.co/1MUM8qiwDl https://t.co/KJcf7rBQAU

• Comparative Effectiveness Randomized Controlled Trials in Rheumatology Guidelin…

GM-CSF inc'd in active AS pts, particularly in younger ages, and strongly correlates with disease activity, but not with disease duration. TNFi tx does not affect GM-SCF levels, despite improving disease activity. Abs 1156 #ACR22 @RheumNow https://t.co/ndhBGbPsCw

• Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in…